Dr. Douglas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9675 Brighton Way
Ste 410
Beverly Hills, CA 90210Phone+1 310-363-8757Fax+1 310-363-8758
Summary
- Dr. Raymond Douglas is an oculoplastics specialist who sees patients at the University of Michigan Kellogg Eye Center in Ann Arbor. Dr. Douglas’ clinical practice focuses on orbital surgery, especially minimally invasive surgery, and decompressions for thyroid-associated eye disease. He also performs cosmetic facial surgeries including blepharoplasty, eyelid lift, midface lift, fillers for under-eye hollows, and Botox injections as well as post-cancer reconstruction including Mohs surgery.
Dr. Douglas is well known for his clinical expertise and research on Graves’ eye disease and is the Director of Kellogg’s Thyroid Eye Disease Clinic. His research focuses on Graves' eye disease, autoimmune diseases of the orbit, and minimally invasive approaches to the orbit. To make an appointment, please call Kellogg’s Thyroid Eye Disease Clinic at 734-764-5106. To refer a patient, please visit www.kellogg.umich.edu/refer.
Education & Training
- University of Pennsylvania Health System/Scheie Eye InstituteResidency, Ophthalmology, 1999 - 2002
- Perelman School of Medicine at the University of PennsylvaniaClass of 1998
Certifications & Licensure
- CA State Medical License 2002 - 2026
- IL State Medical License 2023 - 2026
- FL State Medical License 2023 - 2025
- NV State Medical License 2023 - 2025
- NY State Medical License 2014 - 2025
- MI State Medical License 2008 - 2019
- PA State Medical License 1999 - 2002
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease Start of enrollment: 2013 Jul 01
- Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Start of enrollment: 2017 Oct 04
- Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Start of enrollment: 2018 Apr 16
Publications & Presentations
PubMed
- 215 citationsEvidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves’ DiseaseShanli Tsui, Vibha Naik, Neil Hoa, Catherine J. Hwang, Nikoo F. Afifiyan
Journal of Immunology. 2008-09-15 - 28 citationsBiologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy.Vibhavari M. Naik, Nicole M. Khadavi, Milind N. Naik, Cathy Hwang, Robert A. Goldberg
Thyroid. 2008-09-12 - 81 citationsTeprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-m...George J. Kahaly, Raymond S Douglas, Robert J. Holt, Saba Sile, Terry J. Smith
The Lancet. Diabetes & Endocrinology. 2021-04-15
Journal Articles
- Teprotumumab for the Treatment of Active Thyroid Eye DiseaseRaymond Douglas, MD, The New England Journal of Medicine
- Objectively Measuring Observer Attention in Severe Thyroid‐Associated Orbitopathy: A 3D StudyLisa E Ishii, Halley M Darrach, Andrew W Joseph, Raymond S Douglas, David Liao, Masaru Ishii, The Laryngoscope
Press Mentions
- RVL Pharmaceuticals Announces That Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty AwardsApril 10th, 2023
- Thrive Health Infusion Centers Launch for Thyroid Eye Disease in Tandem with Thyroid Awareness MonthJanuary 25th, 2023
- Teprotumumab May Be Effective in Thyroid Eye Disease with Less InflammationNovember 15th, 2021
- Join now to see all
Grant Support
- The Role Of CD40+ Fibrocytes In Thyroid Associated OphthalmopathyNational Eye Institute2011–2012
- Immune Activation Of FibroblastsNational Eye Institute2008
- Immune Activation Of FibroblastsNational Eye Institute2004–2008
Professional Memberships
- Fellow
- Member
External Links
- Surgical Rehabilitation of Thyroid Eye Disease http://www.youtube.com/watch?v=RmNy1eLrnj8
- Optimizing TED Therapy: Minimally Invasive Optionshttp://www.youtube.com/watch?v=KjpsF4r3Qwk
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: